Table Info

Table 4.

Unique proteins from the induction group reported as DAMPs and their interacting receptors on immune cells

S.No	Unique in induction	Interaction with immune receptor	Role as a DAMP
1	KRT9	PRRs	Yes
2	KRT1	PRRs	Yes
3	ACTB	DNGR-1	Yes
4	ACTG1	DNGR-1	Yes
5	SERPINF1	Under investigation	Yes
6	C3	C3b (CR1)	Yes
7	HBA1	TLR4	Yes
8	KRT2	PRR, TLR, RAGE	Yes
9	KRT10	TLR	Yes
10	OLFML3	Iba1	Yes
11	HSPB1	PRR	Yes
12	C4B	PRR	Yes
13	TUBB	PRR	Yes
14	RBP4	TLR4	Yes
15	TUBB1	PRR	Yes
16	COL1A2	PRR, TLR	Yes
17	AHSG	RAGE	Yes
18	PPIA	CD147	Yes
19	PKM	No specific receptor	Yes
20	APOE	VLDLR, ApoER2	Yes
21	COL6A1	α1β1 and α2β1	Yes
22	COTL1	F-actin	No data available
23	ENO1	PRR	Yes
24	C9	No specific receptor	Yes
25	GAPDH	TLR2, 4, RAGE	Yes
26	RAP1B	PRR	Yes
27	RAP1A	RAGE	Yes
28	RP1BL	No specific receptor listed	Yes
29	CLU	RAGE	Yes
30	PGK1	TLR2, 4	Yes
31	APOB	LDLR, PRR, TLR	Yes
32	HSPA1B	TLR2, 4, CD14, CD91	Yes
33	HSPA1L	TLR2, 4	Yes
34	HSP90AA1	TLR2, 4	Yes
35	FLNA	TLR2, 4	Yes

PRR: pattern recognition receptors; TLR: toll like receptors; DNGR-1: dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin; CR: complement receptor; RAGE: receptor for advanced glycation end products; Iba-1: ionized calcium-binding adapter molecule 1: CD147: cluster of differentiation 147; VLDLR: very low-density lipoprotein receptor; ApoER2: apolipoprotein E receptor 2; α1β1 and α2β1: alpha-1 beta-1 integrin; LDLR: low-density lipoproteins receptors

Supplementary materials

The supplementary figures for this article are available at: https://www.explorationpub.com/uploads/Article/file/1003194_sup_1.pdf.

Declarations

Author contributions

BT, AD, and AKR: Data curation, Investigation, Methodology, Project administration, Software, Validation, Visualization, Writing—original draft. RV: Software, Validation, Visualization, Methodology, Writing—original draft. YK and AB: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing—review & editing.

Conflicts of interest

The authors declare that there is no conflict of interest involved.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Datasets are available on request: The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

The authors acknowledge the funding support provided by PGIMER for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

References

Linkermann A, Stockwell BR, Krautwald S, Anders H. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol. 2014;14:759–67. [DOI] [PubMed]

Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541. [DOI] [PubMed] [PMC]

Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–9. [DOI] [PubMed]

Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008;135:1161–3. [DOI] [PubMed]

Thakur B, Kumar Y, Bhatia A. Programmed necrosis and its role in management of breast cancer. Pathol Res Pract. 2019;215:152652. [DOI] [PubMed]

Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res. 2014;16:204. [DOI] [PubMed] [PMC]

Krysko O, Aaes TL, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis. 2013;4:e631. [DOI] [PubMed] [PMC]

Sangiuliano B, Pérez NM, Moreira DF, Belizário JE. Cell death-associated molecular-pattern molecules: inflammatory signaling and control. Mediators Inflamm. 2014;2014:821043. [DOI] [PubMed] [PMC]

Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, et al. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol. 2015;6:402. [DOI] [PubMed] [PMC]

10.

Vrakas CN, O’Sullivan RM, Evans SE, Ingram DA, Jones CB, Phuong T, et al. The Measure of DAMPs and a role for S100A8 in recruiting suppressor cells in breast cancer lung metastasis. Immunol Invest. 2015;44:174–88. [DOI] [PubMed]

11.

Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21:69–78. [DOI] [PubMed] [PMC]

12.

Gong T, Liu L, Jiang W, Zhou R. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol. 2020;20:95–112. [DOI] [PubMed]

13.

Thakur B, Saha L, Bhatia A. Relative refractoriness of breast cancer cells to tumour necrosis factor-α induced necroptosis. Clin Exp Pharmacol Physiol. 2022;49:1294–306. [DOI] [PubMed]

14.

Thakur B, Saha L, Dahiya D, Bhatia A. Effect of aspirin on the TNF-α-mediated cell survival and death pathways in breast cancer. J Basic Clin Physiol Pharmacol. 2022;34:91–102. [DOI] [PubMed]

15.

Lee K, Lee H, Han D, Moon WK, Kim K, Oh HJ, et al. Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. Breast Cancer Res. 2020;22:130. [DOI] [PubMed] [PMC]

16.

Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L, et al. Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death Differ. 2020;27:2768–80. [DOI] [PubMed] [PMC]

17.

Thakur B, Verma R, Bhatia A. Mutations in Necroptosis-Related Genes Reported in Breast Cancer: A Cosmic and Uniport Database-Based Study. Clin Breast Cancer. 2024;S1526–820900356–2. [DOI] [PubMed]

18.

Koo G, Morgan MJ, Lee D, Kim W, Yoon J, Koo JS, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res. 2015;25:707–25. [DOI] [PubMed] [PMC]

19.

Khorsandi L, Orazizadeh M, Niazvand F, Abbaspour MR, Mansouri E, Khodadadi A. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. Bratisl Lek Listy. 2017;118:123–8. [DOI] [PubMed]

20.

Shahsavari Z, Karami-Tehrani F, Salami S. Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7. Anticancer Agents Med Chem. 2018;18:245–54. [DOI] [PubMed]

21.

Murao A, Aziz M, Wang H, Brenner M, Wang P. Release mechanisms of major DAMPs. Apoptosis. 2021;26:152–62. [DOI] [PubMed] [PMC]

22.

Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. Transplantation and Damage-Associated Molecular Patterns (DAMPs). Am J Transplant. 2016;16:3338–61. [DOI] [PubMed]

23.

Denning N, Aziz M, Gurien SD, Wang P. DAMPs and NETs in Sepsis. Front Immunol. 2019;10:2536. [DOI] [PubMed] [PMC]

24.

Wu Chuang A, Kepp O, Kroemer G, Bezu L. Endoplasmic reticulum stress in the cellular release of damage-associated molecular patterns. Int Rev Cell Mol Biol. 2020;350:1–28. [DOI] [PubMed]

25.

Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, et al. Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression. Cancers (Basel). 2021;13:645. [DOI] [PubMed] [PMC]

26.

Cai Z, Zhang A, Choksi S, Li W, Li T, Zhang X, et al. Activation of cell-surface proteases promotes necroptosis, inflammation and cell migration. Cell Res. 2016;26:886–900. [DOI] [PubMed] [PMC]

27.

Zhang X, Yin M, Zhang L. Keratin 6, 16 and 17-Critical Barrier Alarmin Molecules in Skin Wounds and Psoriasis. Cells. 2019;8:807. [DOI] [PubMed] [PMC]

28.

Díaz-Ramos A, Roig-Borrellas A, García-Melero A, López-Alemany R. α-Enolase, a multifunctional protein: its role on pathophysiological situations. J Biomed Biotechnol. 2012;2012:156795. [DOI] [PubMed] [PMC]

29.

Tu S, Chang C, Chen C, Tam K, Wang Y, Lee C, et al. Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010;121:539–53. [DOI] [PubMed]

30.

Seny Dd, Cobraiville G, Charlier E, Neuville S, Lutteri L, Goff CL, et al. Apolipoprotein-A1 as a damage-associated molecular patterns protein in osteoarthritis: ex vivo and in vitro pro-inflammatory properties. PLoS One. 2015;10:e0122904. [DOI] [PubMed] [PMC]

31.

Kang N, Ji Z, Li Y, Gao J, Wu X, Zhang X, et al. Metabolite-derived damage-associated molecular patterns in immunological diseases. FEBS J. 2024;291:2051–67. [DOI] [PubMed]

32.

Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114:2367–74. [DOI] [PubMed]

33.

Wang H, Kim SJ, Lei Y, Wang S, Wang H, Huang H, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024;9:235. [DOI] [PubMed] [PMC]

34.

Ahrens S, Zelenay S, Sancho D, Hanč P, Kjær S, Feest C, et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. Immunity. 2012;36:635–45. [DOI] [PubMed]

35.

Zhang JG, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity. 2012;36:646–57. [DOI] [PubMed]

36.

Nami B, Wang Z. Genetics and Expression Profile of the Tubulin Gene Superfamily in Breast Cancer Subtypes and Its Relation to Taxane Resistance. Cancers (Basel). 2018;10:274. [DOI] [PubMed] [PMC]

37.

Xia L, Xiao X, Liu WL, Song Y, Liu TJJ, Li YJ, et al. Coactosin-like protein CLP/Cotl1 suppresses breast cancer growth through activation of IL-24/PERP and inhibition of non-canonical TGFβ signaling. Oncogene. 2018;37:323–31. [DOI] [PubMed]

38.

Huerta-Reyes M, Maya-Núñez G, Pérez-Solis MA, López-Muñoz E, Guillén N, Olivo-Marin J, et al. Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs. Front Oncol. 2019;9:943. [DOI] [PubMed] [PMC]

39.

Aoudjit F, Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother Res Pract. 2012;2012:283181. [DOI] [PubMed] [PMC]

40.

Calaf GM, Abarca-Quinones J. Ras protein expression as a marker for breast cancer. Oncol Lett. 2016;11:3637–42. [DOI] [PubMed] [PMC]

41.

Zhang W, Wang M, Ji C, Liu X, Gu B, Dong T. Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials. Biomed Pharmacother. 2024;177:116930. [DOI] [PubMed]

42.

Fagone P, Rosa MD, Palumbo M, Gregorio CD, Nicoletti F, Malaguarnera L. Modulation of heat shock proteins during macrophage differentiation. Inflamm Res. 2012;61:1131–9. [DOI] [PubMed]

43.

Fearing BV, Dyke MEV. In vitro response of macrophage polarization to a keratin biomaterial. Acta Biomater. 2014;10:3136–44. [DOI] [PubMed]

44.

Fréret M, Rottenberg P, Calbo S, Lequerré T, Vittecoq O. 08.02 Alpha-enolase promotes pro-inflammatory phenotype of monocytes-derived macrophages in vitro. Ann Rheum Dis. 2017;76:A75. [DOI]

45.

Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L, et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol. 2024;8:31. [DOI] [PubMed] [PMC]